Detail akcie Amar Bioscienc Hldg online

Business Summary: Amarantus Bioscience Holdings, Inc. is a biopharmaceutical holding company. The Company has approximately three operating divisions: the diagnostics division, the therapeutics division and the drug discovery division. It owns licenses to various product candidates in the therapeutic and diagnostic sectors of the life sciences industry. It is developing diagnostic product candidates in the field of neurology, and therapeutic product candidates in the areas of neurology, psychiatry, ophthalmology and regenerative medicine. The Company, through its subsidiary, Cutanogen Corporation, is developing a regenerative medicine cell therapy-based autologous skin replacement product, Engineered Skin substitute, which is in mid-stage clinical development, for the treatment of life-threatening severe burns. It is also developing a mid-stage clinical-stage pharmaceutical drug candidate, Eltoprazine, a small molecule 5HT1a/1b partial agonist for the treatment of symptomatic neurological disorders.
Financial Summary: BRIEF: For the three months ended 31 March 2016, Amarantus Bioscience Holdings Inc revenues was not reported. Net loss applicable to common stockholders increased 70% to $12.6M. Higher net loss reflects Interest Expense increase from $42K to $1.3M (expense), Other expense increase from $0K to $51K (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$0.93 to -$0.37.